• Home
  • News
  • Press Releases

SomaGenics launches miR-ID® platform for highly sensitive and specific quantification of microRNAs (miRNAs)

SANTA CRUZ, Calif., October 6, 2015- SomaGenics, Inc. today announced the launch of its novel miR-ID® platform for detecting miRNA using a circularization-based RT-qPCR method.  miR-ID® is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule.  The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.

Continue Reading

Somagenics Awarded 2-Year NIH grant to develop NGS microRNA Library Technology

SANTA CRUZ, Calif., April 2015 – Somagenics has been awarded a two-year NIH grant to develop its novel RealSeq™–T technology for targeted next-generation sequencing (NGS) of small RNAs such as microRNA.

There is increasing interest in using NGS for miRNA biomarker discovery from biofluids such as blood plasma as well as for miRNA expression profiling and diagnostic purposes. There are many advantages to using NGS, including unlimited multiplexing, high sensitivity, sequence specificity and ability to detect miRNA sequence editing.  Targeted NGS brings these advantages to the quantification of any specific  group of sequences of interest.  However, sequence bias in the construction of the small RNA libraries used in sequencing has so far limited the utility of NGS, both targeted and non-targeted. This bias gives distorted small RNA profiles and renders some species of RNA that might be good biomarkers unavailable for accurate quantification.

Continue Reading

Three SomaGenics Publications Demonstrate Successful Inhibition of the Hepatitis C Virus by Therapeutic sshRNA™ and Confirm Mechanism of Action

SANTA CRUZ, Calif., Dec. 19, 2014 — SomaGenics and collaborators have published exciting results on the efficacy of RNA interference (RNAi) therapeutics against the hepatitis C virus (HCV) based on the company's sshRNA™ platform. Using a chimeric mouse model with humanized liver that supports infection by HCV, SomaGenics scientists and their collaborators from Roche and Tekmira Pharmaceuticals demonstrated efficient sshRNA delivery to the liver, potent and long-lasting reduction in viral load, and strong evidence for a direct anti-viral effect by the sshRNAs. The studies were published in Molecular Therapy-Nucleic acids, in Gastroenterology, and in the Journal of Virology.

Continue Reading